Name: Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery (Video) | JoVE Journal
Uploaded: 2026-04-14T13:35:00.000+00:00
Duration: 4 min 36 s
Description: Learn the standardized surgical protocol for Foldable Capsular Vitreous Body implantation in complex retinal detachment cases. This technique encapsulates silicone oil to minimize complications and enhance long-term intraocular safety.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors thank the patients and clinical staff at Xi&#8217;an People&#8217;s Hospital for their support. No financial support was received for this study.

This protocol describes a standard surgical technique using an approved medical device and does not involve experimental interventions. Therefore, formal institutional ethics committee approval was not required. Written informed consent was obtained from all patients or their legal guardians prior to surgery, in accordance with the principles of the Declaration of Helsinki.
1. Preoperative preparation12
<ol>
	<li>Select appropriate patients, including those with severe ocular trauma (e.g., perforating injury, choroidal rupture), recurrent retinal detachment, silicone oil-dependent eyes, endophthalmitis, or hypotony with corneal opacity.</li>
	<li>Exclude patients meeting any of the following contraindications: (1) Patients are allergic to the silicone rubber or the scar diathesis; (2) Entophthalmia; (3) Uveitis; (4) The lens of the treated eye is transparent; (5) Patients have proliferative diabetic retinopathy; (6) The corrected visual acuity of the contralateral eye is &#8804; 0.4; (7) The contralateral eye has an anamnesis of an internal surgery of the eye; (8) The patients have other uncontrollable eye diseases; (9) The patients have a severe renal and hepatic impairment and/or some severe systemic diseases (e.g., cardiovascular, respiratory, digestive, neurological, endocrine, and genitourinary diseases); (10) Pregnant or lactating women; (11) The patients have a history of drug abuse or alcoholism.</li>
	<li>Perform preoperative imaging: B-scan ultrasonography and UBM to assess anterior and posterior segments; where possible, use OCT and three-dimensional MRI reconstruction of the vitreous cavity to determine the appropriate FCVB model and silicone oil volume.</li>
	<li>Prepare all materials and instruments listed in the Table of Materials</li>
	<li>Ensure the surgical team is familiar with device handling, including identification of the capsule surface, drainage valve orientation, and fixation loop.</li>
	<li>Preoperatively fold a demonstration device at least once to become familiar with the process.</li>
	<li>Administer topical antibiotics and anti-inflammatory agents for 3 days prior to surgery. Measure corneal diameter and intraocular pressure, and photograph the anterior segment.</li>
</ol>
2. Intraoperative Steps12
<ol>
	<li>Perform the procedure under general anesthesia or retrobulbar anesthesia according to the patient&#39;s condition and institutional practice. For general anesthesia, induce anesthesia using intravenous agents such as propofol (1.5&#8211;2.5 mg/kg) combined with short-acting opioid analgesics (e.g., remifentanil or fentanyl), with or without a neuromuscular blocking agent as required for airway management. Maintain oxygen supplementation at approximately 2 L/min.</li>
	<li>Create conjunctival peritomy at the 10:30 and 4:30 positions. Using a 9-0 polypropylene suture with a long needle, enter the sclera 5 mm posterior to the limbus at 10:30 and exit 4 mm posterior at 4:30.</li>
	<li>Perform a leakage test by injecting balanced salt solution into the capsule before implantation.</li>
	<li>Evacuate the capsule to vacuum without inverting its curvature. Fold the capsule tightly from top to bottom and secure the center with a 5-0 external suture. 
	CAUTION: Avoid contact between sharp instruments and the capsule to prevent microperforation or valve damage.</li>
	<li>Create a scleral tunnel incision (3.5&#8211;4.5 mm wide, based on implant size) 2 mm posterior to the limbus between the 9 and 12 o&#8217;clock positions.</li>
	<li>Introduce the pre-folded device into the vitreous cavity using intraocular lens platform forceps. Once half of the capsule is inserted, cut the temporary suture and begin silicone oil injection.</li>
	<li>Connect a silicone oil injection system to the drainage valve, and purge air from the tubing. Insert the needle vertically into the center of the drainage valve using gentle, controlled pressure to avoid tearing the valve. Initiate silicone oil injection at a slow, controlled rate (approximately 0.05&#8211;0.1 mL/s) under continuous visualization. Adjust injection pressure using the injector&#8217;s low-pressure or manual-assist mode to allow gradual capsule expansion. 
	CAUTION: Excessive injection speed or pressure may cause valve damage or asymmetric capsule expansion.</li>
	<li>Use an iris repositor to gently rotate and position the FCVB so that the lens-facing surface is oriented anteriorly and the drainage tube lies at the predetermined scleral exit site (typically the 10:30 position). Confirm correct orientation by visualizing symmetric capsule expansion and absence of folding or torsion.</li>
	<li>Close the scleral tunnel incision with 10-0 nylon sutures. Restore the anterior chamber with viscoelastic.</li>
	<li>Secure the fixation sutures in a Z-shaped scleral tunnel. Close the conjunctiva and Tenon&#8217;s capsule with 8-0 absorbable suture.</li>
	<li>Administer subconjunctival injections of tobramycin and dexamethasone. Apply topical antibiotic and steroid ointment. 
	CAUTION: Apply a pressure dressing to the operated eye to immobilize the globe and prevent postoperative bleeding.</li>
</ol>
3. Postoperative management12
<ol>
	<li>Position the patient prone for the first week, then maintain a prone or lateral position for up to 3 months. Avoid supine positioning.</li>
	<li>Prescribe topical tobramycin-dexamethasone eye drops 4x daily for 2 months, tapered based on clinical response.</li>
	<li>Apply atropine 1% ointment once daily for 2 weeks, then switch to compound tropicamide eye drops for 1 month.</li>
	<li>In cases of severe inflammation, administer periocular triamcinolone acetonide (10 mg) weekly for up to 3 weeks.</li>
	<li>If hypotony, shallow anterior chamber, or exudative membrane formation is detected within 1&#8211;3 months postoperatively, viscoelastic material should be administered to both the anterior and posterior chambers, together with 1 mg of triamcinolone acetonide (TA) in the anterior chamber and 10 mg of TA via periocular injection. If these conditions recur during subsequent follow-up, the same intervention should be repeated, for a maximum of two additional treatments, to facilitate the gradual recovery of ciliary body function.</li>
	<li>Manage complications such as hypotony or shallow anterior chamber with intracameral viscoelastic and triamcinolone acetonide (1 mg). Repeat if necessary.</li>
	<li>Schedule follow-up visits at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, and annually thereafter. At each visit, assess visual acuity, intraocular pressure, retinal status, and device position. 
	NOTE: This protocol is intended for vitreoretinal surgeons with formal fellowship-level training or equivalent experience in complex vitreoretinal surgery. Prior experience with silicone oil tamponade and scleral fixation techniques is strongly recommended before performing FCVB implantation independently.</li>
</ol>
4. Typical postoperative complications and management
<ol>
	<li>Hypotony
	<ol>
		<li>Manage postoperative hypotony (IOP &#60; 6 mmHg) with intracameral viscoelastic (0.1&#8211;0.2 mL) to restore chamber depth. If imaging shows insufficient silicone oil, perform a supplemental injection. Ensure the patient is in a prone or lateral position and monitor the IOP digitally.</li>
	</ol>
	</li>
	<li>Shallow anterior chamber
	<ol>
		<li>A shallow anterior chamber may result from underfilling or malposition of the foldable capsular buckle. Ensure preoperative 3D-guided device sizing, silicone oil adjustment, intracameral viscoelastic injection, and balloon repositioning.</li>
	</ol>
	</li>
	<li>Corneal opacification
	<ol>
		<li>Corneal opacification is usually related to endothelial stress or anterior chamber shallowing. Assess the endothelial cell density at 2 weeks postoperatively. Treat with viscoelastic to deepen the chamber and with standard anti-inflammatory and mydriatic therapy.</li>
	</ol>
	</li>
</ol>

<ol><li>Gao, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+new+strategy+to+replace+the+natural+vitreous+by+a+novel+capsular+artificial+vitreous+body+with+pressure-control+valve%5BTitle%5D)+AND+%22Eye%22%5BJournal%5D)">A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve.</a> Eye. 22 (3), 461-468 (2008).</li>
<li>Foster, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Vitreous+substitutes%5BTitle%5D)+AND+%22Expert+Rev+Ophthalmol%22%5BJournal%5D)">Vitreous substitutes.</a> Expert Rev Ophthalmol. 3 (2), 211-218 (2008).</li>
<li>Inoue, M., Iriyama, A., Kadonosono, K., Tamaki, Y., Yanagi, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effects+of+perfluorocarbon+liquids+and+silicone+oil+on+human+retinal+pigment+epithelial+cells+and+retinal+ganglion+cells%5BTitle%5D)+AND+%22Retina%22%5BJournal%5D)">Effects of perfluorocarbon liquids and silicone oil on human retinal pigment epithelial cells and retinal ganglion cells.</a> Retina. 29 (5), 677-681 (2009).</li>
<li>Giordano, G. G., Refojo, M. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Silicone+oils+as+vitreous+substitutes%5BTitle%5D)+AND+%22Prog+Polym+Sci%22%5BJournal%5D)">Silicone oils as vitreous substitutes.</a> Prog Polym Sci. 23 (3), 509-532 (1998).</li>
<li>Tan, H. S., Oberstein, S. Y., Mura, M., Bijl, H. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Air+versus+gas+tamponade+in+retinal+detachment+surgery%5BTitle%5D)+AND+%22Br+J+Ophthalmol%22%5BJournal%5D)">Air versus gas tamponade in retinal detachment surgery.</a> Br J Ophthalmol. 97 (1), 80-82 (2013).</li>
<li>Montoya, A. M., de Smet, M. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Air+as+tamponade+for+retinal+detachment%5BTitle%5D)+AND+%22Eur+J+Ophthalmol%22%5BJournal%5D)">Air as tamponade for retinal detachment.</a> Eur J Ophthalmol. 24 (2), 242-246 (2014).</li>
<li>Fu, A. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Complications+of+general+anesthesia+using+nitrous+oxide+in+eyes+with+preexisting+gas+bubbles%5BTitle%5D)+AND+%22Retina%22%5BJournal%5D)">Complications of general anesthesia using nitrous oxide in eyes with preexisting gas bubbles.</a> Retina. 22 (5), 569-574 (2002).</li>
<li>Kopecek, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hydrogel+biomaterials%3A+a+smart+future%5BTitle%5D)+AND+%22Biomaterials%22%5BJournal%5D)">Hydrogel biomaterials: a smart future.</a> Biomaterials. 28 (34), 5185-5192 (2007).</li>
<li>Swindle, K. E., Hamilton, P. D., Ravi, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+situ+formation+of+hydrogels+as+vitreous+substitutes%3A+viscoelastic+comparison+to+porcine+vitreous%5BTitle%5D)+AND+%22J+Biomed+Mater+Res+A%22%5BJournal%5D)">In situ formation of hydrogels as vitreous substitutes: viscoelastic comparison to porcine vitreous.</a> J Biomed Mater Res A. 87 (3), 656-665 (2008).</li>
<li>Gupta, H., Jain, S., Mathur, R., Mishra, P., Mishra, A. K., Velpandian, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sustained+ocular+drug+delivery+from+a+temperature+and+pH+triggered+novel+in+situ+gel+system%5BTitle%5D)+AND+%22Drug+Deliv%22%5BJournal%5D)">Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system.</a> Drug Deliv. 14 (8), 507-515 (2007).</li>
<li>Cavalieri, F., Miano, F., D’Antona, P., Paradossi, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Study+of+gelling+behavior+of+poly%28vinyl+alcohol%29-methacrylate+for+potential+utilizations+in+tissue+replacement+and+drug+delivery%5BTitle%5D)+AND+%22Biomacromolecules%22%5BJournal%5D)">Study of gelling behavior of poly(vinyl alcohol)-methacrylate for potential utilizations in tissue replacement and drug delivery.</a> Biomacromolecules. 5 (6), 2439-2446 (2004).</li>
<li>Yan, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Consensus+on+the+treatment+of+severe+ocular+trauma+and+silicone+oil-dependent+eyes+using+foldable+capsular+vitreous+body%5BTitle%5D)+AND+%22J+Evid+Based+Med%22%5BJournal%5D)">Consensus on the treatment of severe ocular trauma and silicone oil-dependent eyes using foldable capsular vitreous body.</a> J Evid Based Med. 18 (2), e70041(2025).</li>
<li>Liu, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Technical+standards+of+a+foldable+capsular+vitreous+body+in+terms+of+mechanical%2C+optical%2C+and+biocompatible+properties%5BTitle%5D)+AND+%22Artif+Organs%22%5BJournal%5D)">Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties.</a> Artif Organs. 34 (10), 836-845 (2010).</li>
<li>Schwartz, S. G., Flynn, H. W. Jr, Mieler, W. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Update+on+retinal+detachment+surgery%5BTitle%5D)+AND+%22Curr+Opin+Ophthalmol%22%5BJournal%5D)">Update on retinal detachment surgery.</a> Curr Opin Ophthalmol. 24 (3), 255-261 (2013).</li>
<li>Ocular Trauma Group of the Ophthalmology Branch, Chinese Medical Association. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Top+ten+research+advances+in+ocular+trauma+in+China+over+the+past+five+years.+%28%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E4%BC%9A%E7%9C%BC%E7%A7%91%E5%AD%A6%E5%88%86%E4%BC%9A%E7%9C%BC%E5%A4%96%E4%BC%A4%E5%AD%A6%E7%BB%84%E6%88%91%E5%9B%BD%E7%9C%BC%E5%A4%96%E4%BC%A4%E8%BF%91%E4%BA%94%E5%B9%B4%E5%8D%81%E5%A4%A7%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95%29%5BTitle%5D)+AND+%22Zhonghua+Yan+Ke+Za+Zhi%22%5BJournal%5D)">Top ten research advances in ocular trauma in China over the past five years. (中华医学会眼科学分会眼外伤学组我国眼外伤近五年十大研究进展).</a> Zhonghua Yan Ke Za Zhi. 51, 604-607 (2015).</li>
<li>Abu Serhan, H., Irshaidat, S., Abu Serhan, L., Elnahry, A. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Foldable+capsular+vitreous+body+indications%2C+complications%2C+and+outcomes%3A+a+systematic+review%5BTitle%5D)+AND+%22Graefes+Arch+Clin+Exp+Ophthalmol%22%5BJournal%5D)">Foldable capsular vitreous body indications, complications, and outcomes: a systematic review.</a> Graefes Arch Clin Exp Ophthalmol. 261 (8), 2103-2116 (2023).</li>
<li>Liu, Y. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+efficacy+and+safety+of+foldable+capsular+vitreous+body+implant+surgery+in+22+cases+of+silicone+oil-dependent+eyes%5BTitle%5D)+AND+%22Curr+Med+Sci%22%5BJournal%5D)">Clinical efficacy and safety of foldable capsular vitreous body implant surgery in 22 cases of silicone oil-dependent eyes.</a> Curr Med Sci. 43 (2), 393-398 (2023).</li>
<li>Kolipaka, G. P., Rao, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Secondary+glaucoma+following+vitreo-retinal+surgeries%5BTitle%5D)+AND+%22Indian+J+Ophthalmol%22%5BJournal%5D)">Secondary glaucoma following vitreo-retinal surgeries.</a> Indian J Ophthalmol. 71 (1), 18-25 (2023).</li>
<li>Miller, J. B., Papakostas, T. D., Vavvas, D. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Complications+of+emulsified+silicone+oil+after+retinal+detachment+repair%5BTitle%5D)+AND+%22Semin+Ophthalmol%22%5BJournal%5D)">Complications of emulsified silicone oil after retinal detachment repair.</a> Semin Ophthalmol. 29 (5-6), 312-318 (2014).</li>
<li>Parikh, H. A., Kalbag, N. S., Zarbin, M. A., Bhagat, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Characteristics%2C+demographics%2C+outcomes%2C+and+complications+of+diabetic+traction+retinal+detachments+treated+with+silicone+oil+tamponade%5BTitle%5D)+AND+%22Eur+J+Ophthalmol%22%5BJournal%5D)">Characteristics, demographics, outcomes, and complications of diabetic traction retinal detachments treated with silicone oil tamponade.</a> Eur J Ophthalmol. 26 (5), 497-502 (2016).</li>
<li>McCuen, B. W. 2nd, Rinkoff, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Silicone+oil+for+progressive+anterior+ocular+neovascularization+after+failed+diabetic+vitrectomy%5BTitle%5D)+AND+%22Arch+Ophthalmol%22%5BJournal%5D)">Silicone oil for progressive anterior ocular neovascularization after failed diabetic vitrectomy.</a> Arch Ophthalmol. 107 (5), 677-682 (1989).</li>
<li>Ma, S., Zhao, S., Zhang, C., Tang, X., Zhou, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Study+on+the+efficacy+and+safety+of+foldable+capsular+vitreous+body+in+the+severe+retinal+detachment+eyes%5BTitle%5D)+AND+%22BMC+Ophthalmol%22%5BJournal%5D)">Study on the efficacy and safety of foldable capsular vitreous body in the severe retinal detachment eyes.</a> BMC Ophthalmol. 22 (1), 491(2022).</li>
<li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Study+on+the+effectiveness+and+safety+of+foldable+capsular+vitreous+body+implantation%5BTitle%5D)+AND+%22BMC+Ophthalmol%22%5BJournal%5D)">Study on the effectiveness and safety of foldable capsular vitreous body implantation.</a> BMC Ophthalmol. 19 (1), 260(2019).</li>
<li>Jiang, G., Lin, Y., Chen, Y., Wu, H., Huang, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Timing+of+intravitreal+foldable+capsular+vitreous+body+implantation+after+silicone+oil+tamponade%5BTitle%5D)+AND+%22Graefes+Arch+Clin+Exp+Ophthalmol%22%5BJournal%5D)">Timing of intravitreal foldable capsular vitreous body implantation after silicone oil tamponade.</a> Graefes Arch Clin Exp Ophthalmol. 263 (12), 3555-3562 (2025).</li>
</ol>

The authors have no conflicts of interest to declare.

Within this manuscript, intraoperative and postoperative images demonstrate procedural checkpoints indicating correct execution of the protocol, such as complete capsule unfolding, correct orientation, and anatomical stabilization. In contrast, statements regarding safety, complication rates, and long-term outcomes are derived from previously published studies and should be interpreted as literature-supported expectations rather than outcomes demonstrated by this protocol.
The FCVB implantatio...

Retinal detachment remains a sight-threatening condition, particularly in eyes with severe ocular trauma, multiple recurrences, or prolonged dependence on intraocular tamponade. Silicone oil is widely used as a vitreous substitute in complex vitreoretinal surgery because it provides long-term internal support; however, direct contact between silicone oil and intraocular tissues has been associated with complications such as emulsification, corneal endothelial damage, secondary glaucoma, hypotony, and long-term silicone oil dependence1. Despite their widespread clinical use, no currently available vitreous substitute fully meets the requirements for long-term anatomical support with minimal complications in complex cases.
Internationally, vitreous substitutes used in clinical practice include silicone oil, expansile gases, and emerging investigational materials such as hydrogels. Based on existing research, current mainstream vitreous substitutes each have their specific indications and limitations. Silicone oil, as a long-term tamponade agent, effectively supports the retina and maintains intraocular pressure, particularly in cases of complex retinal detachment. However, its prolonged retention may lead to complications such as emulsification, secondary glaucoma, cataract, and corneal pathologies2,3,4. Expanding gases (e.g., SF6 and C3F8) provide effective surface tension for short-term tamponade and are commonly used in pneumatic retinopexy. Nevertheless, they require patients to maintain specific postures, carry a risk of postoperative intraocular pressure elevation, and are limited due to restrictions on air travel5,6,7. Emerging hydrogels (e.g., PVA and PAA) are designed to mimic the rheological and biological functional properties of the natural vitreous, demonstrating good biocompatibility and potential as drug delivery carriers8,9,10. However, further optimization is still needed regarding their long-term in vivo stability, precise control of degradation behavior, and injectability through small-gauge needles8,11.
The Foldable Capsular Vitreous Body (FCVB), is a Class III implantable medical device developed as a novel vitreous substitute designed to address limitations associated with conventional vitreous substitutes12. The FCVB consists of a capsule, drainage tube, drainage valve, and fixation loop, fabricated as a single unit through high-temperature and high-pressure molding of medical-grade silicone polymer13. Its design is based on a computerized simulation of the vitreous cavity, allowing personalized sizing and implantation. The core mechanism of the FCVB lies in its innovative capsule design. Made of medical-grade silicone polymer and shaped based on computer simulations of the human vitreous cavity, the capsule can form a physically isolated chamber after implantation, encapsulating the filling material (such as silicone oil) to prevent direct contact with and damage to intraocular tissues such as the retina and ciliary body12. This fundamental design shift addresses issues caused by direct tissue contact in traditional silicone oil tamponade, such as emulsification, toxicity, and chronic inflammation. Based on published clinical studies, the practical implications of this design include: 1) Maintaining ocular structure and intraocular pressure: By supporting the posterior chamber space, the capsule aids in the recovery of ciliary body function and helps maintain stable intraocular pressure12; 2) Significantly reducing long-term complications: Physical isolation effectively lowers the risks associated with prolonged silicone oil retention, such as emulsification, secondary glaucoma, and corneal pathologies12; 3) Providing a new option for eye preservation in severe cases: Particularly suitable for severe post-traumatic retinal detachment, cases with multiple surgical failures, and silicone oil-dependent eyes where conventional vitreous substitutes are ineffective, the FCVB offers a novel therapeutic approach for patients who might otherwise face phthisis bulbi or enucleation12.
First introduced in clinical practice in 2012, the FCVB was recognized as one of the four major advances in global retinal detachment surgery in 201314 and was listed among China&#8217;s Top Ten Ophthalmological Achievements in 201515. The device is particularly valuable in eyes with severe trauma, recurrent detachment, silicone oil dependence, and impaired ciliary function16. Published evidence on FCVB implantation includes early experimental studies, prospective clinical case series, and systematic reviews evaluating its safety and clinical performance in complex vitreoretinal conditions12. Commonly reported endpoints include retinal reattachment status, rates of silicone oil emulsification, secondary glaucoma, corneal complications, intraocular pressure stability, and long-term globe preservation. Across these studies, FCVB implantation has been associated with lower rates of silicone oil emulsification and improved intraocular pressure stability compared with conventional silicone oil tamponade, particularly in eyes with silicone oil dependence or ciliary body dysfunction. These findings provide a growing clinical rationale for the use of FCVB in selected complex cases, while underscoring the need for standardized surgical techniques12.
This article describes a standardized, step-by-step protocol for FCVB implantation, including preoperative planning, intraoperative surgical technique, and postoperative management, to provide a reproducible instructional guide for vitreoretinal surgeons.

<table><tbody><tr><td>Anesthetic agent</td><td>As per institutional protocol</td><td></td><td>Local or general anesthesia&lt;br/&gt; Quantity: 1</td></tr><tr><td>Balanced saline solution (BSS) / sterile normal saline</td><td>&amp;mdash;</td><td></td><td>30ml&lt;br/&gt; Quantity: 1</td></tr><tr><td>Caliper</td><td>&amp;mdash;</td><td></td><td>Ophthalmic surgical caliper&lt;br/&gt; Quantity: 1</td></tr><tr><td>Foldable Capsular Vitreous Body (FCVB)</td><td>Guangzhou Vesber Biotechnology</td><td></td><td>Size determined preoperatively&lt;br/&gt; (AV-10P, AV-10PX, AV-12P, AV-13.5P, AV-15P, and AV-17P)&lt;br/&gt; Quantity: 2</td></tr><tr><td>Intraocular lens (IOL) implantation forceps</td><td>&amp;mdash;</td><td></td><td>Ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Iris repositor</td><td>&amp;mdash;</td><td></td><td>Ophthalmic type&lt;br/&gt; Quantity: 1</td></tr><tr><td>Lid speculum</td><td>&amp;mdash;</td><td></td><td>Adult ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Lint-free sterile gloves</td><td></td><td></td><td>Quantity: 1</td></tr><tr><td>Microsurgical forceps (non-toothed)</td><td>&amp;mdash;</td><td></td><td>Ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Microsurgical forceps (toothed)</td><td>&amp;mdash;</td><td></td><td>Ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Microsurgical scissors (angled)</td><td>&amp;mdash;</td><td></td><td>Ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Needle (25G) or 25G vitrectomy trocar needle</td><td>&amp;mdash;</td><td></td><td>25-gauge&lt;br/&gt; Quantity: 1</td></tr><tr><td>Ophthalmic viscosurgical device (sodium hyaluronate)</td><td>Bausch + Lomb</td><td></td><td>1 mL&lt;br/&gt; Quantity: 1</td></tr><tr><td>Positioning hook</td><td>&amp;mdash;</td><td></td><td>Ophthalmic&lt;br/&gt; Quantity: 1</td></tr><tr><td>Silicone oil</td><td>Bausch + Lomb</td><td></td><td>VRL600&lt;br/&gt; Quantity: 1</td></tr><tr><td>Silicone oil</td><td>Fluoron (Germany)</td><td></td><td>Siluron 5000&lt;br/&gt; Quantity: 1</td></tr><tr><td>sterile beaker</td><td>&amp;mdash;</td><td></td><td>30 mL&lt;br/&gt; Quantity: 1</td></tr><tr><td>Sterile gauze pads</td><td>&amp;mdash;</td><td></td><td>Quantity: 1</td></tr><tr><td>Sterile syringe</td><td>&amp;mdash;</td><td></td><td>2 mL&lt;br/&gt; Quantity: 1</td></tr><tr><td>Sterile syringe</td><td>&amp;mdash;</td><td></td><td>10 mL&lt;br/&gt; Quantity: 1</td></tr><tr><td>Suture, absorbable (Vicryl)</td><td>Ethicon</td><td></td><td>7-0&lt;br/&gt; Quantity: 1</td></tr><tr><td>Suture, non-absorbable</td><td>&amp;mdash;</td><td></td><td>10-0, Model 8065307901&lt;br/&gt; Quantity: 1</td></tr><tr><td>Suture, non-absorbable</td><td>&amp;mdash;</td><td></td><td>5-0</td></tr><tr><td>Suture, non-absorbable (US)</td><td>&amp;mdash;</td><td></td><td>10-0&lt;br/&gt; Quantity: 1</td></tr></tbody></table>

implantation protocol of the foldable capsular vitreous body for complex vitreoretinal surgery

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

The Foldable Capsular Vitreous Body (FCVB) is an implantable vitreous substitute designed to provide internal tamponade in eyes with complex vitreoretinal conditions. This protocol describes a standardized surgical procedure for FCVB implantation via a scleral incision, followed by silicone oil injection. The protocol outlines key preoperative considerations, including patient selection and device sizing, followed by detailed intraoperative steps, including capsule folding, insertion into the vitreous cavity, controlled silicone oil injection, device positioning, and scleral fixation. Postoperative management strategies, including patient positioning, medication regimens, and follow-up evaluation, are also described to support procedural reproducibility.
This protocol is intended for adult patients aged 18 to 65 years, with no sex-related restrictions. Eligible subjects must have a best-corrected visual acuity of less than 0.05 in the treated eye, an ocular axial length ranging from 16 to 28 mm, and present with severe retinal detachment that cannot be effectively managed using currently available vitreous substitutes. Previous clinical studies have reported that FCVB implantation can reduce silicone oil&#8211;related complications, such as emulsification and secondary glaucoma, by physically isolating silicone oil from intraocular tissues. These reported outcomes provide the clinical rationale for the use of FCVB but are not generated by this protocol itself. By presenting a step-by-step surgical workflow and highlighting critical technical considerations, this protocol serves as an instructional guide for vitreoretinal surgeons seeking to perform FCVB implantation or adapt the technique to their own surgical settings.

To evaluate the clinical relevance of the proposed procedure, we reviewed previously published studies reporting postoperative complication rates following FCVB implantation and conventional silicone oil tamponade. The data are summarized and compared to highlight differences in safety profiles between the two approaches (Table 1).
Published studies consistently demonstrate that accurate FCVB folding and implantation (Figure 1) result in lower rat...

The Foldable Capsular Vitreous Body (FCVB) is an intraocular implant that encapsulates silicone oil within a flexible capsule to reduce silicone oil-related complications. This protocol describes the surgical implantation of the FCVB via scleral incision for the treatment of complex retinal detachment and ocular trauma.

The Foldable Capsular Vitreous Body (FCVB) is an implantable vitreous substitute designed to provide internal tamponade in eyes with complex vitreoretinal ...

Retinal detachment is a severe blinding disorder. Management becomes particularly challenging in cases of complex trauma, multiple recurrences, or eyes requiring longterm intraocular tamponade. Silicone oil is widely used as a vitreous substitute.However, direct contact with the intraocular tissue may cause emulsification, secondary glaucoma, and corneal endothelial damage. To address these limitations, a Foldable Capsular Vitreous Body was developed. Made of medical-grade silicone rubber, the FCVB encapsulated silicone oil within a capsule, physically isolating from intraocular tissues, and thereby reducing related complications.This video demonstrates the standardized surgical procedure for FCVB implantation, including preoperative preparation, key surgical steps, and postoperative outcomes. Perform the procedure under general retrobulbar anesthesia according to patient condition and institutional practice. Create conjunctival peritomy at the 10:30 and 4:30 positions.Using a 9-0 polypropylene suture with a long needle, enter the sclera five millimeter posterior to the limbus at 10:30 and exit four millimeter posterior at 4:30. Construct a scleral tunnel incision two millimeter posterior to the limbus between the 9 and 12 o'clock positions. Before implantation, perform a leakage test by injecting balanced salt solution into the capsule.Avoid contact between sharp instruments and the device. Evacuate the capsule to create a vacuum while preserving its curvature. Fold the capsule tightly from top to bottom and secure the center temporary with a 5-0 external suture.Insert the pre-folded device into the vitreous cavity using intraocular lens platform forceps. After approximately half of the capsule has entered the eye, cut the temporary suture and begin silicone oil injection. Tilt the lens-facing surface horizontally using an iris repositor to properly position the device.Ensure the drainage tube is located at the 10:30 position. Close the scleral tunnel incision with 10-0 nylon sutures. Restore the anterior chamber with viscoelastic.Secure the fixation sutures using a Z-shaped scleral tunnel. Close the conjunctiva and Tenon's capsule using 8-0 absorbable sutures. Published studies demonstrate that accurate FCVB implantation significantly reduces silicone oil emulsification, secondary glaucoma, and corneal complications compared with conventional silicone oil tamponade.No cases of phthisis bulbi have been reported in FCVB-treated patients. Postoperative slit-lamp and fundus examinations typically show preserved globe integrity, stable anterior chamber depth, and sustained posterior segment support. When performed correctly, the FCVB remains centrally positioned with capsule collapse, valve leakage, or device migration.Restoration and maintenance of posterior chamber depth serve as key anatomical indicators of successful implantation. FCVB implantation of the transformative solution for complex retinal detachment and silicone oil-dependent eyes, by isolating silicone oil with a capsule, it significantly enhances long-term intraocular safety. As a refined surgical technique, it requires precise handling and meticulous execution.This video presents a standardized protocol based on current expert consensus, providing surgeons with practical guidance to preserve the globe in patients at risk of enucleation.

implantation-protocol-foldable-capsular-vitreous-body-for-complex

Research

JoVE Journal

Medicine

This video demonstrates a novel capsulorhexis technique in modern cataract surgery. Capsulorhexis is the most difficult and important part of phacoemulsification surgery.

A Novel Capsulorhexis Technique Using Shearing Forces with Cystotome

The paper describes a simplified technique to excise corneal and to eviscerate retinal tissues from the ocular globe of human cadaveric donors. The technique described here will help to excise good quality tissues to be used for transplantation, surgical or research purposes without damaging other tissues of the ocular globe.

A Simplified Technique for In situ Excision of Cornea and Evisceration of Retinal Tissue from Human Ocular Globe

Here we describe histological techniques for visualising ocular tissue directly adjacent to a metal epiretinal tack and retinal prosthesis.

Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks

Retinal pigment epithelium (RPE) replacement strategies and gene-based therapy are considered for several retinal degenerative conditions. For clinical translation, large eye animal models are required to study surgical techniques applicable in patients. Here we present a rabbit model for subretinal surgery geared towards RPE transplantation, which is versatile and cost-efficient.

A Step by Step Protocol for Subretinal Surgery in Rabbits

Retinal pigment epithelial cells could serve as a cell-replacement therapy for the advanced form of dry age-related macular degeneration. This protocol describes the generation of a large-eyed model of geographic atrophy and the subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelial cells into this model of disease.

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Presented here is a surgical technique for transplanting human pluripotent stem cell (hPSC)-derived retinal tissue into the subretinal space of a large animal model.

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

The non-human primate (NHP) is an ideal model for studying human retinal cellular therapeutics due to the anatomical and genetic similarities. This manuscript describes a method for submacular transplantation of retinal pigment epithelial cells in the NHP eye and strategies to prevent intraoperative complications associated with macular manipulation.

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

The subretinal implantation of retinal pigmented epithelium (RPE) is one of the most promising approaches for the treatment of degenerative retinal diseases. However, the performance of preclinical studies on large-eye animal models remains challenging. This report presents guidelines for the subretinal transplantation of RPE on a cell carrier into minipigs.

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

The present protocol describes removing residual epithelial cells by rotating the intraocular lens in extracapsular cataract surgery without extra tools for preventing posterior capsular opacification.

Rotating the Intraocular Lens to Prevent Posterior Capsular Opacification in Cataract Surgeries

This protocol presents a transpupillary vision-guided trans-scleral approach to safely and precisely deliver subretinal cellular grafts, with a low rate of surgical complications, in mouse recipients with or without retinal degeneration.

Transpupillary-Guided Trans-Scleral Transplantation of Subretinal Grafts in a Retinal Degeneration Mouse Model

Learn the standardized surgical protocol for Foldable Capsular Vitreous Body implantation in complex retinal detachment cases. This technique encapsulates silicone oil to minimize complications and enhance long-term intraocular safety.

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

Explore More Videos